Introduction
============

Endometrial cancer (EC) comprises a biologically and clinically heterogeneous group of tumors, generally classified as Type I (endometrioid) or Type II (non-endometrioid) on the basis of morphological characteristics. It was recently demonstrated that these two groups are characterized by different genetic alterations; consequently, the function of these variations has been widely investigated, in order to identify diagnostic and prognostic markers for improving the delineation of EC ([@b1-or-41-03-1560]).

Recently, a novel classification system was published by The Cancer Genome Atlas (TCGA) on the basis of genetic and epigenetic modifications ([@b2-or-41-03-1560]). In addition, a previous TCGA-based analysis has confirmed that \>90% of endometrioid EC (EEC) harbor genetic alterations in the phosphoinositide 3-kinase (PI3K) signaling pathway ([@b3-or-41-03-1560]), primarily concerning PI3K catalytic subunit α (*PIK3CA*), and phosphatase and tensin homolog (*PTEN*) ([@b3-or-41-03-1560]--[@b12-or-41-03-1560]).

Furthermore, it has been identified that grade 3 (G3) EEC exhibits clinical and pathological behavior between type I and type II, suggesting that EEC may evolve by mechanisms different from those for other EEC grades ([@b13-or-41-03-1560]--[@b16-or-41-03-1560]).

In EEC, the frequency of *PIK3CA* mutations is 50% ([@b17-or-41-03-1560]) making it one of the most frequently mutated genes ([@b18-or-41-03-1560]--[@b21-or-41-03-1560]), independently of histological types ([@b17-or-41-03-1560],[@b22-or-41-03-1560]). In total, \>70% of *PIK3CA* mutations cluster at three 'hotspot' codons, exon 1 (p.R88Q), exon 9 (p.E542K, p.E545K/G/A, p.Q546R) and exon 21 (p.H1047R/L/Y, p.M1043I/V) ([@b17-or-41-03-1560],[@b23-or-41-03-1560]), each of which induces its constitutive activation ([@b3-or-41-03-1560],[@b24-or-41-03-1560]--[@b26-or-41-03-1560]). However, the association between genetic variations and endometrial carcinogenesis remains poorly understood. Several studies have identified different correlations between *PIK3CA* variations and tumor grade, stage and type ([@b5-or-41-03-1560],[@b6-or-41-03-1560],[@b26-or-41-03-1560]--[@b29-or-41-03-1560]).

*PTEN* somatic mutations have been reported in several types of gynecological tumor; in addition, PTEN inactivation is present in endometriosis and endometrial hyperplasia, and may be considered an early event in cancer development ([@b30-or-41-03-1560]--[@b33-or-41-03-1560]). In EECs, *PTEN* mutations have been identified ([@b16-or-41-03-1560]), and PTEN protein loss was revealed to be correlated with overall survival (OS) ([@b34-or-41-03-1560]).

As suggested by TCGA, the PI3K signaling pathway may represent a potential target for targeted therapy for the treatment of EC ([@b3-or-41-03-1560],[@b23-or-41-03-1560]). Indeed, several PI3K pathway inhibitors have been developed and are currently under investigation in preclinical studies, and in early clinical trials ([@b35-or-41-03-1560]), with various results depending on the therapeutic agent used and treatment set-up ([@b8-or-41-03-1560],[@b18-or-41-03-1560],[@b20-or-41-03-1560],[@b22-or-41-03-1560],[@b24-or-41-03-1560],[@b26-or-41-03-1560],[@b29-or-41-03-1560],[@b36-or-41-03-1560]--[@b44-or-41-03-1560]). Nevertheless, it is currently unclear how *PIK3CA* and *PTEN* mutations affect the sensitivity to inhibitors in EC ([@b45-or-41-03-1560]--[@b47-or-41-03-1560]). Consequently, efforts should be focused on improving the characterization of the *PIK3CA* and *PTEN* mutational profiles, to allow the establishment of personalized targeted therapy.

Several approaches may be used for the characterization of mutations \[e.g. next-generation sequencing (NGS), mass spectrometry (MS), Sanger sequencing, polymerase chain reaction (PCR)-high-resolution melting analysis (HRMA) and quantitative PCR (qPCR)\]. Certain methods (i.e. NGS and MS) provide a comprehensive overall evaluation with high specificity and sensitivity, but require expensive instrumentation and procedures, and trained personnel; other methods (i.e. Sanger sequencing, PCR-HRMA and qPCR) are simpler and more cost-effective, but allow the analysis of only a limited number of selected exons, and the specificity and sensitivity differ (Sanger sequencing had high specificity and low sensitivity, and vice versa for PCR-HRMA, whereas qPCR is sensitive and specific, but allows the analysis of only single known hotspots) ([@b48-or-41-03-1560]--[@b51-or-41-03-1560]).

The present pilot study had two main aims: i) To develop an economical and efficient combined procedure on the basis of PCR-HRMA and Sanger sequencing for evaluating the presence of variants in *PIK3CA* (exons 1, 9 and 21) and *PTEN* (exons 5, 6, 7 and 8) genes with the intention to overcome the limitations of each technique; and ii) to assess the presence of the primary mutations in *PIK3CA* and *PTEN* in a selected homogeneous subgroup of G3 EECs.

Materials and methods
=====================

### Tissue collection and DNA extraction

A total of 18 available and suitable tissues were selected from patients with G3 EEC and with at least 2 years of follow up (up to 1 February 2018). All patients underwent surgical treatment between May 2013 and November 2015, at the Obstetrics and Gynecology Unit, Careggi University Hospital (Florence, Italy). Patients were treated depending on International Federation of Gynecology and Obstetrics (FIGO staging), grading and European Society of Gynecological Oncology (ESGO) risk ([@b52-or-41-03-1560]). Tumor samples were collected at the time of surgery, following acquisition written informed consent from the patients. The study was approved by the Ethics Committee of Careggi University Hospital. Patients\' demographic, clinical and pathological features are presented in [Table I](#tI-or-41-03-1560){ref-type="table"}.

Tumor samples were immediately fixed in formalin and processed for paraffin embedding. The resulting formalin-fixed paraffin-embedded (FFPE) tissues were examined histologically by pathologists at Careggi University Hospital for the selection of areas containing \>70% of tumor cells.

DNA was extracted from slices using a QIAamp DNA FFPE tissue kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s protocol. DNA quality (ratio R) and quantity (DNA concentration) were determined using a spectrophotometer (NanoDrop^®^ 1000 UV spectrophotometer; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

### Primers and PCR conditions

Primers for selected exons of *PIK3CA* and *PTEN* were custom-made by Sigma-Aldrich; Merck KGaA (Darmstadt, Germany), and were designed to be suitable for Sanger sequencing and PCR-HRMA using primer3web software (version 4.1.0; primer3.ut.ee), checked for specificity and mismatch using Primer-BLAST ([www.ncbi.nlm.nih.gov/tools/primer-blast](www.ncbi.nlm.nih.gov/tools/primer-blast)) and using SNP Check (version 3; [secure.ngrl.org.uk/SNPCheck/snpcheck.htm](secure.ngrl.org.uk/SNPCheck/snpcheck.htm)). Primer sequences are presented in [Table II](#tII-or-41-03-1560){ref-type="table"}.

PCR was performed using the custom primers, Taq PCR core kit (Qiagen GmbH) and the third-generation DNA-intercalating dye Syto 9 (Thermo Fisher Scientific, Inc.). Briefly, 10 ng DNA was amplified using 2 µl master mix (10X), 0.5 µl each primer (10 µM), 0.4 µl dNTPs (10 mM each), 0.4 µl Syto9 (50 µM), 0.1 µl Taq DNA polymerase (5 U/µl) and water in a final volume of 20 µl. Samples were subjected to incubation at 95°C for 5 min, then 40 amplification cycles of 95°C for 30 sec, 56/60°C (56°C for *PTEN* and 60°C for *PIK3CA*) for 45 sec and 72°C for 45 sec, and a final incubation at 72°C for 20 min in a GeneAmp PCR system 9700 (Thermo Fisher Scientific, Inc.).

### HRMA

Amplified samples were submitted to a high-resolution melting (HRM) protocol (95°C for 5 min, 40°C for 1 min, ramping temperature from 72 to 84°C) in a Rotor-gene Q PCR cycler (Qiagen GmbH). The melting curve of each sample was analyzed using melting and HRM software (Rotor-Gene^®^ Q-Pure Detection series software, version 2.1.0, build 9; Qiagen GmbH).

### Sanger sequencing

The amplified and melted PCR products were purified using a QIAquick PCR purification kit (Qiagen GmbH) and sequenced on an ABI 310 genetic analyzer (Thermo Fisher Scientific, Inc.). Briefly, 3 µl purified PCR was added to 1 µl BigDye Terminator, 3.2 µl forward/reverse primer (1 µM), 3.5 µl BigDye Terminator buffer and water in a final volume of 20 µl, and amplified for 25 cycles of 96°C for 10 sec, 59°C for 5 sec and 60°C for 2 min in the GeneAmp PCR system 9700, purified using a DyeEx 2.0 Spin column (Qiagen GmbH), according to the manufacturer\'s protocol, and 7 µl was Sanger sequenced.

To confirm identified mutations, the samples were also sequenced using reverse primers. The electropherogram of each sequenced amplicon was independently evaluated by two individuals. For validation of the combined procedure, in a subgroup of three samples, NGS was performed using Ion Torrent S5 with HotSpot cancer panel version 1 on Chip 520 (Thermo Fisher Scientific, Inc.) with a coverage (mean depth) average of 1,000X, mean reads of 400,000 and mean read length of 115 bp, according to the manufacturer\'s protocol.

For validation of variations identified by PCR-HRMA, but not by Sanger sequencing (sample S2 and S4), their corresponding PCR products associated with *PTEN* exon 5 were cloned using TOPO-TA cloning (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. A total of 20 colonies was isolated and the plasmids were extracted using a QIAprep Spin Miniprep kit (Qiagen GmbH). The extracted plasmids were sequenced as aforementioned.

### Mutation identification

The nucleotide changes were evaluated using the Catalogue of Somatic Mutations in Cancer (COSMIC) database (version 86; [cancer.sanger.ac.uk/cosmic](cancer.sanger.ac.uk/cosmic)), ensembl (release 93; [www.ensembl.org/index.html](www.ensembl.org/index.html)), PolyPhen-2 (version 2; [genetics.bwh.harvard.edu/pph2](genetics.bwh.harvard.edu/pph2)) and Mutation Taster (MT) (version 2; current build, NCBI 37/Ensembl 69; [www.mutationtaster.org](www.mutationtaster.org)) software. Single nucleotide polymorphisms (SNPs) were confirmed using UCSC Genome Browser ([genome.ucsc.edu/](genome.ucsc.edu/)). The clinical impact was evaluated using COSMIC by Functional Analysis Through Hidden Markov Models score (pathogenic score, range: 0, not pathogenic, to 1, pathogenic), for single amino acid substitutions by PolyPhen-2 score (range: 0, not pathogenic, to 1, pathogenic) and for synonymous single amino acid substitutions, complex variations (insertions/deletions/frameshifts) and modifications in intronic sequence by MT \[evaluation: Disease-causing (DC) or SNP\].

Results
=======

### Quality of DNA

The extracted DNAs had sufficient amount and quality for PCR amplification and Sanger sequencing; in particular, the concentration mean was 164.15±2.00 ng/µl; the median was 138.00±2.00 ng/µl; the range was between 18.00 and 299.10 ng/µl; the value of R was 2.15 (mean) and 2.15 (median), and the range was between 2.00 and 2.47.

### Establishment of the combined PCR-HRMA and Sanger sequencing procedure

The combined procedure is based on the sequential execution of PCR-HRMA and Sanger sequencing, without other steps, and avoids double PCR if the two procedures are performed separately with a corresponding saving of DNA, time of execution and limiting the number of mistakes due to performing the analysis twice. All samples were amplified to verify the success of amplification and to perform the HRMA. An appropriate curve was obtained for all the samples and for each analyzed exon. The HRMA suggested the presence of nucleotide alteration(s) without providing direct information on the specific nucleotide change(s), which induced changes in the shape of the HRM and melting curves. In particular, the presence of nucleotide change(s) induced or a shift in the peak or the appearance of additional peak(s) in the melting curve and a change in the shape of the HRM curve. In order to identify associations of the curve shape with a specific nucleotide sequence, the amplicons were sequenced using the Sanger procedure.

[Figs. 1](#f1-or-41-03-1560){ref-type="fig"} and [2](#f2-or-41-03-1560){ref-type="fig"} present representative results of the HRM and melting curves, and the corresponding specific base modification identified by Sanger sequencing, for *PIK3CA* exon 1 and for *PTEN* exon 5, respectively.

The comparison of HRMA and sequencing data confirmed that samples with the same HRM curve shared the same nucleotide sequence. Differences in HRM curves for the same amplicon suggested the presence of different nucleotide sequences. [Figs. 3](#f3-or-41-03-1560){ref-type="fig"} and [4](#f4-or-41-03-1560){ref-type="fig"} present the principal variations detected by HRM curves along with the corresponding nucleotide change(s) for each exon of *PIK3CA* and *PTEN* analyzed. Notably, for *PTEN* exon 5, it was observed that three samples shared the same HRM and melting curves ([Fig. 5](#f5-or-41-03-1560){ref-type="fig"}), but the corresponding Sanger sequences revealed the presence of a specific variant only for one sample (sample S9; p.Y155S), suggesting that the two samples (samples S2 and S4) may have the same variation as sample S9, but at lower levels. To verify this hypothesis, the PCR products of samples S2 and S4 were cloned into a plasmid and sequenced, which confirmed the presence of the suggested variant at low level (two and three positive colonies, respectively, in samples S2 and S4).

This combined approach allowed the avoidance of a double PCR (if the two methodologies were applied separately), retaining DNA for use in further analysis. Furthermore, the use of HRMA alone suggested the presence of homoduplex or heteroduplex variations in the analyzed exons \[*PIK3CA* exon 1 (61%), exon 9 (6%) and exon 21 (33%), and *PTEN* exon 5 (44%), exon 6 (78%), exon 8 (50%) and none in exon 7), but provided information on the type of variation. Sanger sequencing provided this specific information on the type of alteration, allowing the characterization of the nucleotide variation, but with low sensitivity. The merged information provided the sensitivity of HRMA and the specificity of Sanger sequencing (for example, for PTEN exon 5, the mutation detection frequency increased from 33 to 44%).

To further evaluate this approach, three samples were validated using this combined procedure and by NGS technology in which all the *PTEN* and *PIK3CA* exons were analyzed, as well as 48 other cancer-associated genes. The two technologies yielded the same results: For sample S16 only, a single-base mutation in *PTEN* exon 5 was detected.

Evaluation of variants on PIK3CA and PTEN
-----------------------------------------

### PIK3CA

A total of seven different variations in 11 samples (61%) were identified, all of which were heterozygous, except for IVS1+40A\>G (intronic) which in three samples was homozygous and 7/11 were pathogenic ([Table III](#tIII-or-41-03-1560){ref-type="table"}). In particular, in exon 1, two mutations were identified, namely p.L89R (6%) and p.R88G (18%), as well as the SNP IVS1+40A\>G (rs3729674; 44%); in exon 9, the mutation p.Q546R (cosm12459; 6%), was identified; and in exon 21, the mutation p.H1047P (cosm249874; 22%) and the variant p.E1037Q (12%) were detected. The highest number of mutations (three mutations and one variant) was observed in exon 21 compared with exon 1 (two mutations) and exon 9 (one mutation). All five samples at FIGO stage III (IIIA and IIIC) did not exhibit any variation in *PIK3CA*.

### PTEN

A total of 12 different variations were identified and 16/18 (89%) samples exhibited at least one variation, among which 12 (67%) presented a pathological variation ([Table IV](#tIV-or-41-03-1560){ref-type="table"}). In particular, exon 6 exhibited the highest number of variations. The most represented alteration was p.Q171Q (78%), followed by p.R189K (cosm1745951; 44%). Exon 5 exhibited pathogenic mutations in six samples (33%): p.Y155S (18%), p.D162H (cosm5274; 12%), p.Y155H (cosm5038; 6%), p.G143fs\*4 (cosm30623; 6%), R130\* (cosm5152; 6%) and G129Stop (cosm18663; 6%). Exon 8 had an intronic variant (IVS8+32T\>G; 44%) and in one sample it was associated with p.I300fs\*2. Exon 7 did not present any mutation according to Kafshooz *et al* ([@b53-or-41-03-1560]). No particular trend was observed for the *PTEN* mutation, except for the non-menopausal patient that had PTEN R130\* and the presence of the *PTEN* T167fs\* in the obese class III patient.

### Variant/mutational load

Regarding the overall variant evaluation, the majority of the samples (89%) exhibited at least one variation ([Table V](#tV-or-41-03-1560){ref-type="table"}). Regarding SNPs, 50% of the samples exhibited one SNP and 18% presented with two SNPs.

Regarding the mutations, 67% of the samples had confirmed mutations at least in one of the two genes, whereas 18% had mutations in the two genes, and these values increased to 72 and 33%, respectively, if the mutations predicted with PolyPhen-2 were considered, and to 82 and 39%, respectively, if the MT prediction was considered.

It was observed that 28% of the samples exhibited a single confirmed mutation, 16% exhibited two mutations, 22% exhibited three mutations and 6% exhibited four mutations. Considering the overall variant load (excluding SNPs), 18% of the samples exhibited none, one or four mutations, 10% exhibited two or five mutations, and 26% exhibited three mutations.

No specific mutation/variant load distribution was observed according to clinicopathological characteristics.

Discussion
==========

Currently, there is increasing interest in investigating the genome alterations in tumors, with such research made possible by the development of specific and sensitive technologies (e.g. NGS or MassArray). These promising technologies are useful for understanding the mechanisms underlying carcinogenesis and cancer evolution, but are costly and require computational support for data analysis. For clinical application, the identification of genetic variations must be performed rapidly and cost-effectively, as usually performed by Sanger sequencing/pyrosequencing or PCR-HRMA procedures. Typically, qPCR is performed for confirmation analysis.

It is established that PCR-HRMA has a lower cost and is an accurate tool for mutation scanning, allowing the identification of variations through comparison of HRM curves; consequently, it is used as screening method or for the detection of known hotspot mutations. Its ability in discriminating known mutations is due to the use of reference material, or if this material is not available or novel variations are present in the samples analyzed, the technique is not able to identify the nucleotide change, but only to detect the presence ([@b54-or-41-03-1560]--[@b56-or-41-03-1560]). The HRMA curve shape depends on the number and type of nucleotide changes, with different nucleotide changes yielding different curves. The procedure alone is highly sensitive (overall sensitivity 0.1--5%) ([@b50-or-41-03-1560],[@b51-or-41-03-1560]), but lacks specificity, since it does not allow for the direct evaluation of the specific nucleotide changes. Consequently, for the identification of nucleotide variations, the procedure requires the use of reference materials with the same alteration to be investigated along with the target samples, or further investigations by other techniques (such as sequencing or qPCR).

Sanger sequencing is the reference procedure for the identification of nucleotide changes for clinical purposes; even if this technology is unable to reveal variations at low levels (overall sensitivity \~20%) ([@b48-or-41-03-1560],[@b49-or-41-03-1560]), sometimes pyrosequencing is used due its increased sensitivity. However, this methodology is relatively expensive compared with Sanger sequencing, even if more sensitive ([@b57-or-41-03-1560]).

Currently, other high-throughput methodologies are beginning to be used in the clinic for the identification of genetic variation in clinical samples, such as NGS and MS that allow the evaluation of multiple genes/exons and several samples in the same run. Usually these procedures improve specificity and sensitivity, but are expensive either for their required instrumentation and methodological procedures, provide abundant information that is not useful for clinical purposes, and require trained personnel for data analysis. In particular, MS allows the evaluation of known variations on specific exons/genes; instead NGS allows the evaluation of genes or genome and the identifications of new genetic variants. qPCR, which has high sensitivity and specificity, allows the identification of well-known and characterized variations, but is expensive and time-consuming if several genes or variations require analysis, and is not suitable for the detection of unknown variations. It is typically used for confirmation when Sanger sensitivity fails.

The present study establishes a combined procedure that overcomes the limitations of each technique alone (low sensitivity of Sanger sequencing and low specificity of HRMA) and combines the strengths (high specificity of Sanger sequencing and high sensitivity of HRMA) of these techniques. It also allows a double check for the presence of variants in the main exons of *PIK3CA* and *PTEN*, in order to improve the reliability of the results. The target of this approach is the identification of variants in single samples and in amplicons of between 100 and 200 bp in length; consequently, it cannot be compared with high-throughput procedures. Furthermore, this combined approach, in comparison with the application of either method alone, may decrease the amount of DNA used in the analysis (a single PCR is performed for the two methodologies) and the number of samples analyzed by Sanger sequencing. In particular, if a reference wild-type (wt) sample is used in the PCR-HRMA step, only the samples presenting HRM curves different from the wt should be analyzed by Sanger sequencing. Furthermore, PCR-HRMA can also only suggest the presence of novel variants, but they cannot be identified; by contrast, the combined use of PCR-HRMA and Sanger analysis can immediately confirm and identify the novel variations. This combined procedure may even be useful for defining patient eligibility for targeted therapy; it is known that targeted therapy is dependent on the identification of specific mutations by Sanger sequencing, and its efficacy is determined by the number of mutated cells and by the development of any new mutations that can originate from tumor heterogeneity or *de novo*. Owing to the high sensitivity of HRMA, suspected cases with a low proportion of mutations may still be identified and monitored ([Table VI](#tVI-or-41-03-1560){ref-type="table"}).

The present study focused on the analysis of specific exons of *PIK3CA* and *PTEN*, since these are established as the main genes involved in alterations in the PI3K signaling pathway, and they have been widely investigated for the characterization of EC as specific targets for personalized therapies on the basis of PI3K pathway inhibitors ([@b17-or-41-03-1560],[@b18-or-41-03-1560],[@b20-or-41-03-1560],[@b29-or-41-03-1560],[@b35-or-41-03-1560],[@b40-or-41-03-1560]). Indeed, early clinical data on several tumor types suggested that *PIK3CA* and *PTEN* mutations may affect the success of PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)-targeted therapies ([@b58-or-41-03-1560]--[@b61-or-41-03-1560]). Patients with gynecological tumors and *PIK3CA* mutations have demonstrated a 30% response rate (RR) in early-phase clinical trials with PI3K/AKT/mTOR inhibitors, compared with a 10% RR in patients lacking *PIK3CA* mutations ([@b42-or-41-03-1560]). It is conceivable that loss of PTEN function can be similarly predictive for therapy efficacy, whereas simultaneous mutations in the mitogen-activated protein kinase signaling pathway may lead to resistance to treatment ([@b58-or-41-03-1560],[@b60-or-41-03-1560]). Identifying actionable molecular aberrations has been a critical step for several major therapeutic advances in cancer medicine.

A combined technique was established in the present study for the examination of G3 EEC in order to investigate the involvement of major mutations of the PI3K signaling pathway in this EC subtype, and to ultimately implement the clinical and pathological knowledge of this grade of EEC regardless of differing characteristics (e.g. FIGO stage and ESGO risk). The present pilot study demonstrated that the approach was successful in analyzing G3 EEC, specifically for the genetic profile of selected *PIK3CA* and *PTEN* exons.

It was observed, in the cohort of the present study, that several samples were wt for specific exons (from 22% of *PTEN* exon 6 to 100% of *PTEN* exon 7) and that the overall number of variations was broad (in a single sample there were up to three variations for *PTEN* exon 6 and up to seven variations overall).

The focus was on the *PIK3CA* exons 1, 9, and 21, and on the *PTEN* exons 5, 6, 7 and 8 since these are typically the more frequently mutated exons in EECs; indeed, in a previous study, Rudd *et al* ([@b17-or-41-03-1560]), when investigating all *PIK3CA* and *PTEN* exons, identified that no other exons were involved in G3 EEC. Furthermore, to verify this result and to partially validate the combined methodological approach, three samples were analyzed by NGS obtained the same results. Nevertheless, not examining all exons of *PTEN* and *PIK3CA* is a limitation of the present study, and perhaps something to perform in the future.

Using the approach developed in the present study, the overall evaluation revealed that 89% of samples exhibited at least one variation in either of the two genes, and that 83% had mutations. Regarding *PIK3CA*, 39% of samples exhibited mutations, among which the most frequent were H1047P (27%), p.T1025A (7%) and p.Q546R (7%) ([@b7-or-41-03-1560],[@b17-or-41-03-1560],[@b21-or-41-03-1560],[@b22-or-41-03-1560]). With regard to *PTEN*, 67% of the samples had mutations, including p.R189K (53%), p.D132H (13%), p.Y155H (7/%) and p.R130\* (7%).

As aforementioned, the overall mutational load was determined as at least one mutation in 83% of the samples and coexistence of mutations in the two genes in 33% of the samples. An increased mutation frequency was identified for each single gene compared with the coexistence of mutations, in contrast with results reported previously ([@b27-or-41-03-1560]), particularly those reported by Oda *et al* ([@b6-or-41-03-1560]), which may be due to the specific evaluation of the G3 subgroup of EEC in the present study.

It was observed that the FIGO stage III tumors did not exhibit any mutation in *PIK3CA*, and that the patient with class III obesity had *PIK3CA* p.Q546 and *PTEN* p.T167fs\* mutations, suggesting an association supported by a previous study of the association of obesity and EC through the involvement of the PI3K signaling pathway ([@b62-or-41-03-1560]).

The preliminary data of the present study indicated potential for the use of a combined technological approach for the identification of variants in *PIK3CA* and *PTEN*. Although they are preliminary results owing to the limited number of samples analyzed, the data confirm the involvement of PI3K pathway alterations in G3 EEC; however, further investigation is required.

In conclusion, the present study has demonstrated the suitability and reliability of a combined approach (PCR-HRMA and Sanger sequencing) for the evaluation of variants in selected exons of *PIK3CA* and *PTEN* in G3 EEC, suggesting that this approach may be useful for improving the classification and personalized treatment of patients with EC.
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![High-resolution melting curves associated with the principal identified phosphatase and tensin homolog gene variants. Each curve represents an exemplificative sample. 'wt' corresponds to a sample(s) that presented no variation in the specific amplicon in comparison with the GenBank reference sequence. (A) Exon 5. (B) Exon 6. (C) Exon 6. (D) Exon 7. (E) Exon 8. For each sample, the corresponding identified variants are presented in [Table IV](#tIV-or-41-03-1560){ref-type="table"}. wt, wild-type.](OR-41-03-1560-g03){#f4-or-41-03-1560}

![Investigation of phosphatase and tensin homolog exon 5 variant c.464A\>C by HRM analysis in samples S9 (red), S2 (light blue) and S4 (blue). S11 represents the reference 'wt' (sample with no variations in this amplicon). (A) HRM curves. (B) Melting curves. HRM, high-resolution melting; wt, wild-type.](OR-41-03-1560-g04){#f5-or-41-03-1560}

###### 

Demographic and clinicopathological features of patients with grade 3 endometrioid endometrial cancer.

  Sample   BMI      Age at surgery, years   Menopause, status   Menopause duration years   Myometrial, infiltration %   FIGO stage   Time disease-free, months   Total follow-up, months   LVSI   Lymph node involvement (n)   Risk
  -------- -------- ----------------------- ------------------- -------------------------- ---------------------------- ------------ --------------------------- ------------------------- ------ ---------------------------- -------------------
    S1     Ow       57                      Yes                 4                          \>50                         IB           22                          58                        No     No                           High
  S2       Nw       74                      Yes                 29                         \>50                         IB           --                          56                        No     No                           High
  S3       Ob II    65                      Yes                 15                         \>50                         IIIC         --                          42                        No     3                            Advanced
  S4       Ob II    78                      Yes                 23                         \>50                         IB             6                         38                        No     No                           High
  S5       Ow       60                      Yes                 9                          \>50                         IB           --                          37                        Yes    No                           High
  S6       Ob II    68                      Yes                 16                         \>50                         IIIA         --                          36                        Yes    No                           High
  S7       Nw       54                      Yes                 1                          \>50                         IB           --                          36                        Yes    No                           High
  S8       Ob I     72                      Yes                 20                         \>50                         II           20                          37                        No     No                           High
  S9       Nw       80                      Yes                 31                         \>50                         IB           --                          36                        Yes    No                           High
  S10      Ob III   80                      Yes                 30                         \>50                         IB           --                          34                        Yes    No                           High
  S11      Ob I     79                      Yes                 30                         \>50                         II           --                          34                        No     No                           High
  S12      Nw       77                      Yes                 24                         \>50                         IB           25                          32                        Yes    No                           High
  S13      Nw       43                      No                  --                         \<50                         IA           --                          31                        No     No                           High-intermediate
  S14      Ob II    74                      Yes                 15                         \<50                         IA           --                          30                        Yes    No                           High-intermediate
  S15      Ow       69                      Yes                 13                         \<50                         IA           --                          28                        No     No                           High-intermediate

BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; Nw, normal weight; Ow, overweight; Ob I, obesity class I; Ob II, obesity class II; Ob III, obesity class III.

###### 

Primer sequences.

  Gene       Exon   Forward primer                  Reverse primer                  Product size, bp
  ---------- ------ ------------------------------- ------------------------------- ------------------
  *PIK3CA*   1      5′-TGTTACTCAAGAAGCAGAAAGGG-3′   5′-ACGAAGGTATTGGTTTAGACAGA-3′   231
             9      5′-AGGGAAAATGACAAAGAACA-3′      5′-ACCTGTGACTCCATAGAAA-3′       124
             21     5′-TGCTCCAAACTGACCAAACTG-3′     5′-TGCATGCTGTTTAATTGTGTGG-3′    299
  *PTEN*     5      5′-TGTGAAGATCTTGACCAATGGC-3′    5′-AAATTCTCAGATCCAGGAAGAGG-3′   231
             6      5′-ACGACCCAGTTACCATAGCA-3′      5′-TGTGAAACAACAGTGCCACT-3′      185
             7      5′-CCTCAGTTTGTGGTCTGCC-3′       5′-GCCAGAGTAAGCAAAACACCT-3′     296
             8      5′-TACCAGGACCAGAGGAAACC-3′      5′-AGCAAGTTCTTCATCAGCTGT-3′     280

###### 

*PIK3CA* variants.

               PIK3CA variants   Pathogenic effect   Reported by COSMIC                                                        
  ----- ------ ----------------- ------------------- -------------------- ---------- ----------------------------------- ----- ------------------------------------------------------------
  S1    IB     Exon 1            IVS1+40A\>G                              No (SNP)   UCSC/dbSNP/ClinVar                  --    --
  S2    IB     Exon 1            c.262C\>G           p.R88G               Yes        PolyPhen-2 (score 0.994)            --    --
  S3    IIIC   --                --                  --                   --         --                                  --    --
  S4    IB     Exon 1            IVS1+40A\>G                              No (SNP)   UCSC/dbSNP/ClinVar                  --    --
  S5    IB     Exon 1            IVS1+40A\>G                              No (SNP)   UCSC/dbSNP/ClinVar                  --    --
               Exon 21           c.3073A\>G          p.T1025A             Yes        COSMIC (FATHMM score 1.00)          Yes   Yes (first)^[a](#tfn3-or-41-03-1560){ref-type="table-fn"}^
               Exon 21           c.3140A\>C          p.H1047P             No (SNP)   Cosmic (FATHMM score 0.96)          Yes   No
  S6    IIIA   --                --                  --                   --         --                                  --    --
  S7    IB     Exon 1            IVS1+40A\>G                              No (SNP)   UCSC/dbSNP/ClinVar                  --    --
               Exon 21           c.3140A\>C          p.H1047P             Yes        Cosmic (FATHMM score 0.96)          Yes   No
  S8    II     Exon 1            IVS1+40A\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                  --    --
               Exon 21           c.3140A\>C          p.H1047P             Yes        Cosmic (FATHMM score 0.96)          Yes   No
  S9    IB     Exon 1            IVS1+40A\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                  --    --
  S10   IB     Exon 1            c.266T\>G           p.L89R               Yes        PolyPhen-2 (score 1.000)            --    --
               Exon 9            c.1637A\>G          p.Q546R              Yes        Cosmic (FATHMM score 0.97)          Yes   Yes (third)^[a](#tfn3-or-41-03-1560){ref-type="table-fn"}^
               Exon 21           c.3140A\>C          p.H1047P             Yes        Cosmic (FATHMM score 0.96)          Yes   No
  S11   II     Exon 1            c.262C\>G           p.R88G               Yes        PolyPhen-2 (score 0.994)            --    --
               Exon 1            IVS1+40A\>G                              No (SNP)   UCSC/dbSNP/ClinVar                  --    --
               Exon 21           c.3109G\>C          p.E1037Q             Yes        PolyPhen-2 (score 0.011)            --    --
                                                                                     Mutation Taster (disease-causing)   --    --
  S12   IB     Exon 1            IVS1+40A\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                  --    --
  S13   IA     Exon 1            c.262C\>G           p.R88G               Yes        PolyPhen-2 (score 0.994)            --    --
               Exon 21           c.3109G\>C          p.E1037Q             No         PolyPhen-2 (score 0.011)            --    --
                                                                                     Mutation Taster (disease-causing)   --    --
  S14   IA     --                --                  --                   --         --                                  --    --
  S15   IA     --                --                  --                   --         --                                  --    --
  S16   IIIA   --                --                  --                   --         --                                  --    --
  S17   IIIC   --                --                  --                   --         --                                  --    --
  S18   IIIC   --                --                  --                   --         --                                  --    --

All the variants were heterozygous, excepted those indicated 'homo' (homozygosity).

This value represents the position of EC in the cosmic ranking for the mutation investigated. FIGO, International Federation of Gynecology and Obstetrics; PIK3CA, phosphoinositide 3-kinase catalytic subunit α; COSMIC, Catalogue of Somatic Mutations in Cancer; EC, endometrial cancer; SNP, single nucleotide polymorphism; FATHMM, Functional Analysis Through Hidden Markov Models.

###### 

*PTEN* variants.

               PTEN variants   Pathogenic effect   Reported by COSMIC                                                                                             
  ----- ------ --------------- ------------------- -------------------- ---------- -------------------------------------------------------------------- --------- ------------------------------------------------------------
  S1    IB     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 8          IVS8+32T\>G                              No (SNP)   UCSC/dbSNP/ClinVar                                                   --        --
  S2    IB     Exon 5          c.464A\>C           p.Y155S              Yes        PolyPhen-2 (score 1.000)                                             --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 8          IVS8+32T\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                                                   --        --
  S3    IIIC   Exon 5          c.484G\>C           p.D162H              Yes        COSMIC (FATHMM score 0.99)                                           Yes       No
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
  S4    IB     Exon 5          c.464A\>C           p.Y155S              Yes        PolyPhen-2 (score 1.000)                                             --        --
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
  S5    IB     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
               Exon 8          IVS8+32T\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                                                             
  S6    IIIA   Exon 5          c.484G\>C           p.D162H              Yes        COSMIC (FATHMM score 0.99)                                           Yes       No
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 8          IVS8+32T\>G                              No (SNP)   UCSC/dbSNP/ClinVar                                                   --        --
  S7    IB     Exon 5          c.425delG           p.G143Afs\*4         No         COSMIC (FATHMM score no.)                                            (ovary)   No
               Exon 5          c.463T\>C           p.Y155H              Yes        COSMIC (FATHMM score 0.97)                                           Yes       Yes (first)^[a](#tfn5-or-41-03-1560){ref-type="table-fn"}^
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
  S8    II     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
  S9    IB     Exon 5          c.464A\>C           p.Y155S              Yes        PolyPhen-2 (score 1.000)                                             --        --
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
               Exon 8          c.899_900delCT      p.I300Nfs\*2         Yes        PolyPhen-2 (score 0.059), associated with an amino acid alteration   --        --
                                                                                   Mutation Taster (disease-causing)                                    --        --
               Exon 8          IVS8+32T\>G                              No (SNP)   UCSC/dbSNP/ClinVar                                                   --        --
  S10   IB     Exon 6          c.497_498insT       p.T167Nfs\*13        Yes        PolyPhen-2 (score 0.999), associated with an amino acid alteration   --        --
                                                                                   Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 8          IVS8+32T\>G homo                         No (SNP)   UCSC/dbSNP/ClinVar                                                             
  S11   II     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
  S12   IB     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
  S13   IA     Exon 5          c.388C\>T           p.R130\*                        COSMIC (FATHMM score 0.95)                                           Yes       Yes (first)^[a](#tfn5-or-41-03-1560){ref-type="table-fn"}^
               Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                              
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
  S14   IA     Exon 8          IVS8+32T\>G                              No (SNP)   UCSC/dbSNP/ClinVar                                                   --        --
  S15   IA     Exon 6          c.513G\>A           p.Q171Q              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c\. 549G\>A         p.K183K              (Yes)      Mutation Taster (disease-causing)                                    --        --
               Exon 6          c.566G\>A           p.R189K              Yes        COSMIC (FATHMM score 0.88)                                           Yes       No
               Exon 8          IVS8+32T\>G                                         UCSC/dbSNP/ClinVar                                                   --        --
  S16   IIIA   --              --                  --                   --         --                                                                   --        --
  S17   IIIC   Exon 5          c.385G\>T           p.G129Stop           Yes        COSMIC (FATHMM score 0.99)                                           Yes       Yes (third)^[a](#tfn5-or-41-03-1560){ref-type="table-fn"}^
  S18   IIIC   --              --                  --                   --         --                                                                   --        --

All the variants were heterozygous, excepted those indicated 'homo' (homozygosity).

This value represents the position of EC in the cosmic ranking for the mutation investigated. FIGO, International Federation of Gynecology and Obstetrics; PTEN, phosphatase and tensin homolog; COSMIC, Catalogue of Somatic Mutations in Cancer; EC, endometrial cancer; SNP, single nucleotide polymorphism; FATHMM, Functional Analysis Through Hidden Markov Models.

###### 

Overall evaluation of *PIK3CA* and *PTEN* variants in the samples analyzed.

  Sample   *PIK3CA* variants                       *PTEN* variants
  -------- --------------------------------------- ----------------------------------------------------------------
  S1       *IVS1+40A\>G*                           p.Q171Q, *IVS8+32T\>G*
  S2       **p.R88G**                              **p.R189K, p.Y155S§**, p.Q171Q, *IVS8+32T\>G*
  S3                                               **p.D162H**, p.Q171Q
  S4       *IVS1+40A\>G*                           **p.R189K, p.Y155S§**, p.Q171Q
  S5       **p.T1025A, p.H1047P**, *IVS1+40A\>G*   **p.R189K**, p.Q171Q, *IVS8+32T\>G*
  S6                                               **p.D162H**, p.Q171Q, *IVS8+32T\>G*
  S7       **p.H1047P**, *IVS1+40A\>G*             **p.Y155H, p.R189K**, *p.G143Afs\*4*, p.Q171Q
  S8       **p.H1047P**, *IVS1+40A\>G*             **p.R189K**, p.Q171Q
  S9       *IVS1+40A\>G*                           **p.R189K**, p.Q171Q, **p.Y155S**, *p.I300Nfs\*2, IVS8+32T\>G*
  S10      **p.Q546R, p.H1047P, p.L89R**           **p.T167Nfs\***13, p.Q171Q, *IVS8+32T\>G*
  S11      **p.R88G**, p.E1037Q, *IVS1+40A\>G*     p.Q171Q
  S12      *IVS1+40A\>G*                           p.Q171Q
  S13      **p.R88G**, p.E1037Q                    **p.R130\*, p.R189K**, p.Q171Q
  S14                                              *IVS8+32T\>G*
  S15                                              **p.R189K**, p.Q171Q, p.K183K, *IVS8+32T\>G*
  S16                                              
  S17                                              **p.G129Stop**
  S18                                              

Italic represents single nucleotide polymorphisms. Bold represents variations predicted as 'pathogenic' using PolyPhen-2. Underlining represents variation predicted as 'pathogenic' using Mutation Taster. Bold and underlining represents variation confirmed as 'pathogenic' by Catalogue of Somatic Mutations in Cancer. PIK3CA, phosphoinositide 3-kinase catalytic subunit α; PTEN, phosphatase and tensin homolog.

###### 

Principal characteristics of the main procedures used for identification of variants in DNA sequence.

                                                  Procedure                                                                                                                                                                    
  ----------------------------------------------- ---------------------------------- ------ ---------------------------------------------------------- ------ -------- ------------------------------------------------------- --------
  Cost per sample                                 Medium                             High   Medium                                                     Low    Medium   Medium                                                  Medium
  Sensitivity                                     High                               High   High                                                       High   Low      Medium                                                  High
  Specificity                                     High                               High   High                                                       Low    High     High                                                    High
  Discovery of novel variant                      No                                 Yes    No                                                         Yes    Yes      Yes/no^[a](#tfn7-or-41-03-1560){ref-type="table-fn"}^   Yes
  Identification of sequence change               Yes                                Yes    Yes                                                        No     Yes      Yes                                                     Yes
  Multiple hotspot within amplicon length         No in the same well/yes in a run   Yes    No/yes^[b](#tfn8-or-41-03-1560){ref-type="table-fn"}^      Yes    Yes      Yes                                                     Yes
  Multi-exon analysis in the same preparation     Yes                                Yes    No                                                         No     No       No                                                      No
  Multi-sample analysis in the same preparation   Yes                                Yes    No                                                         No     No       No                                                      No
  Trained personnel                               Yes                                Yes    No                                                         No     No       Medium                                                  No
  Cost of instrumentation                         High                               High   No/medium^[c](#tfn9-or-41-03-1560){ref-type="table-fn"}^   No     No       Medium                                                  No
  Data analysis                                   Yes                                Yes    No                                                         No     No       No                                                      No

It depends on whether the run is set for detection of targeted variants (easy and less time-consuming) or for identification of a novel mutation (more time-consuming and expensive compared with targeted approach).

It depends on whether a multiplex or singleplex assay is used.

Several instruments are present on the market with a broad range of prices. NGS, next-generation sequencing; PCR, polymerase chain reaction; qPCR, quantitative PCR; HRMA, high-resolution melting analysis.

[^1]: Joint senior authorship
